HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review.

AbstractPURPOSE:
We wanted to systematically review (1) the participation of racial and ethnic minorities in clinical trials of antihypertensive drug therapy and (2) racial differences in the efficacy of these therapies for the prevention of cardiovascular outcomes.
METHODS:
MEDLINE, EMBASE, LILACS, African Index Medicus, and the Cochrane Library were searched from their inception to December 2005 for randomized controlled trials testing the efficacy of antihypertensive drug therapy in preventing myocardial infarction, stroke, revascularization, or cardiovascular death. MEDLINE was also searched from 2005 through 2006. The 2 authors independently assessed studies for inclusion and quality.
RESULTS:
Twenty-eight studies met inclusion criteria. Eight trials reported results by racial subgroup. Trials with black and Hispanic participants (ALLHAT, INVEST, VALUE) found similar primary outcomes, but ALLHAT found a greater magnitude of benefit for blacks on diuretic therapy compared with nonblacks. One trial (PROGRESS) compared Asians with non-Asians, reporting that angiotensin-converting enzyme inhibitors (vs placebo) were equally effective for preventing stroke in both groups. In the LIFE trial, post hoc analyses showed different outcomes for blacks and nonblacks, raising questions about the usefulness of angiotensin-receptor blockers as first-line antihypertensive agents in blacks. In 3 studies conducted exclusively in Asians (JMIC-B, FEVER, NICS-EH), calcium channel blockers were effective in preventing cardiovascular outcomes. No trials described cardiovascular outcomes in Native Americans.
CONCLUSIONS:
Five trials made interethnic group comparisons; 4 had similar primary outcomes for ethnic minorities and whites. Increased minority participation in future studies is needed to determine optimal prevention therapies, especially in outcome-driven trials comparing multidrug antihypertensive treatment regimens.
AuthorsIna U Park, Anne L Taylor
JournalAnnals of family medicine (Ann Fam Med) 2007 Sep-Oct Vol. 5 Issue 5 Pg. 444-52 ISSN: 1544-1717 [Electronic] United States
PMID17893387 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)
Chemical References
  • Antihypertensive Agents
Topics
  • African Americans (statistics & numerical data)
  • Antihypertensive Agents (therapeutic use)
  • Asian Continental Ancestry Group (statistics & numerical data)
  • Cardiovascular Diseases (ethnology, prevention & control)
  • Continental Population Groups
  • Ethnic Groups
  • European Continental Ancestry Group (statistics & numerical data)
  • Global Health
  • Hispanic Americans (statistics & numerical data)
  • Humans
  • Hypertension (drug therapy, ethnology)
  • Randomized Controlled Trials as Topic (statistics & numerical data)
  • Research Subjects
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: